111 related articles for article (PubMed ID: 31900441)
1. Initial results with asciminib in CML.
Romero D
Nat Rev Clin Oncol; 2020 Mar; 17(3):135. PubMed ID: 31900441
[No Abstract] [Full Text] [Related]
2. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
3. Asciminib in Relapsed Chronic Myeloid Leukemia.
Sahin I; Reagan JL
N Engl J Med; 2020 Apr; 382(14):1378-1379. PubMed ID: 32242375
[No Abstract] [Full Text] [Related]
4. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
[No Abstract] [Full Text] [Related]
5. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.
Eşkazan AE
Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V; Luna A; Alonso-Dominguez JM; Estrada N; Boque C; Xicoy B; Giraldo P; Angona A; Alvarez-Larrán A; Sanchez-Guijo F; Ramírez MJ; Mora E; Vélez P; Rosell A; Colorado Araujo M; Cuevas B; Sagüés M; Cortes M; Encinas MP; Casado Montero LF; Moreno Vega M; Serrano L; Gomez V; Garcia-Hernandez C; Lakhwani S; Paz Coll A; de Paz R; Suarez-Varela S; Fernandez-Ruiz A; Perez Lopez R; Ortiz-Fernández A; Jiménez-Velasco A; Steegmann-Olmedillas JL; Hernández-Boluda JC
Blood Cancer J; 2021 Feb; 11(2):16. PubMed ID: 33563899
[No Abstract] [Full Text] [Related]
7. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Tran P; Hanna I; Eggimann FK; Schoepfer J; Ray T; Zhu B; Wang L; Priess P; Tian X; Hourcade-Potelleret F; Einolf HJ
Xenobiotica; 2020 Feb; 50(2):150-169. PubMed ID: 31006307
[TBL] [Abstract][Full Text] [Related]
8. Double trouble for CML.
Sarosiek K
Sci Transl Med; 2017 Apr; 9(384):. PubMed ID: 28381535
[TBL] [Abstract][Full Text] [Related]
9. Asciminib in Relapsed Chronic Myeloid Leukemia. Reply.
Mauro MJ; Hughes TP
N Engl J Med; 2020 Apr; 382(14):1379. PubMed ID: 32242376
[No Abstract] [Full Text] [Related]
10. Asciminib for the treatment of patients with chronic myeloid leukemia.
Cortes J
Clin Adv Hematol Oncol; 2021 Apr; 19(4):207-208. PubMed ID: 33989269
[No Abstract] [Full Text] [Related]
11. Platelet function in patients with chronic myeloid leukemia treated with asciminib.
Nesr G; Laffan M; Claudiani S; Innes A; Apperley J; Milojkovic D
Leuk Lymphoma; 2020 Dec; 61(12):3021-3023. PubMed ID: 32654575
[No Abstract] [Full Text] [Related]
12. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY; Ma J; Zheng QC
J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
[TBL] [Abstract][Full Text] [Related]
13. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
Fernando F; Innes AJ; Claudiani S; Pryce A; Hayden C; Byrne J; Gallipoli P; Copland M; Apperley JF; Milojkovic D
Bone Marrow Transplant; 2023 Jul; 58(7):826-828. PubMed ID: 37015970
[No Abstract] [Full Text] [Related]
14. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
Kockerols CCB; Janssen JJWM; Blijlevens NMA; Klein SK; Van Hussen-Daenen LGM; Van Gorkom GGY; Smit WM; Van Balen P; Biemond BJ; Cruijsen MJ; Corsten MF; Te Boekhorst PAW; Koene HR; Van Sluis GL; Cornelissen JJ; Westerweel PE
Haematologica; 2023 Jan; 108(1):240-244. PubMed ID: 36073515
[No Abstract] [Full Text] [Related]
16. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
17. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
19. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
20. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
